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SUMMARY   Toxoplasma gondii is known to infect a considerable number of mammalian and avian 101 
species, and a substantial proportion of the world’s human population. The parasite has an impressive 102 
ability to disseminate within the host’s body and employs various tactics to overcome the highly 103 
regulatory blood-brain barrier and reside in the brain. In healthy individuals, T. gondii infection is 104 
largely tolerated without any obvious ill effect. However, primary infection in immunosuppressed 105 
patients can result in acute cerebral or systemic disease, and reactivation of latent tissue cysts can lead 106 
to a deadly outcome. It is imperative that treatment of the life-threatening toxoplasmic encephalitis is 107 
timely and effective. Several therapeutic and prophylactic regimens have been used in clinical practice. 108 
Current approaches can control infection caused by the invasive and highly proliferative tachyzoites 109 
but cannot eliminate the dormant tissue cysts. Adverse events, and other limitations, are associated with 110 
the standard pyrimethamine-based therapy and effective vaccines are unavailable. In this review the 111 
epidemiology, economic impact, pathophysiology, diagnosis and management of cerebral 112 
toxoplasmosis are discussed, and critical areas for future research are highlighted. 113 
 114 
KEYWORDS Toxoplasma gondii, toxoplasmic encephalitis, immunocompromised patients, 115 
pathophysiology, diagnosis, treatment116 
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INTRODUCTION 
The opportunistic organism Toxoplasma gondii has reached a global interest due to its public health 
and socioeconomic impacts. This apicomplexan parasite can infect a large number of domestic and wild 
animals, and has infected a significant number of people throughout the world (1). People become 
infected primarily through consuming raw or improperly cooked meat (particularly lamb and pork) 
containing infectious tissue cysts or via ingestion of sporulated oocysts in vegetables, fruits or water 
contaminated with feline feces (2). At the initial infection site in the intestine T. gondii infects various 
immune cells and use them to migrate to and infiltrate the brain, where it employs various strategies to 
overcome the complex cellular structure of the blood-brain-barrier (BBB). In the vast majority of 
individuals with competent immune responses, primary infection is asymptomatic or may produce a 
mild, flu-like illness - and the parasite eventually lies dormant within a tissue cyst. However, in less 
than 10% of infections, a mononucleosis-like syndrome with headache, malaise, fever, cervical 
lymphadenopathy and fatigue may occur (3). Primary T. gondii infection can also cause ocular disease, 
and in pregnant women, can lead to fetal death or brain damage in congenitally infected children (4-6).  
In addition to the three classical clinical forms of toxoplasmosis (ocular, congenital, cerebral), 
association of latent T. gondii infection with a number of behavioral modifications and neuropsychiatric 
disorders has also been reported (7). Recurrence of toxoplasmosis from latency is a frequent cause of 
toxoplasmic encephalitis (TE) in people with immunosuppressive conditions - such as advanced HIV 
infection, organ transplantation, neoplastic disease, or those receiving immunosuppressive therapies 
(e.g. rituximab). These patients are particularly vulnerable to recrudescence of latent infection, wherein 
slowly-dividing bradyzoites transform into rapidly-replicating tachyzoites, which can result in fatal 
consequences (3). Symptoms of TE may include diffuse encephalopathy, headaches, confusion, 
weakness, numbness, incoordination, and seizures. Extra-cerebral manifestations, such as respiratory 
and visual problems can also occur.  
Here, we outline the epidemiology and pathobiology of T. gondii infection as it relates to the 
cerebral form of toxoplasmosis, and we highlight the mechanisms by which this parasite migrates to, 
invades, and colonizes the brain to causes neurological dysfunctions. We also discuss diagnostic 
approaches using molecular methods and neuroimaging techniques to confirm brain involvement in 
infected individuals and summarize current strategies for the treatment and control of TE, particularly 
in immunocompromised patients. Finally, we shed light on new targets for future research that may 




Life-Cycle Forms and Routes of Transmission 
The provenance of the multistage lifecycle of Toxoplasma gondii has been well established. During 
its development, T. gondii progresses through 3 main distinctive forms namely: oocyst (containing 
sporozoites), tachyzoite, and tissue cyst (containing bradyzoites). Oocysts are the final product of sexual 
reproduction and are formed exclusively in the intestine of infected felines. The obligate intracellular 
tachyzoite and the bradyzoite represent the two main stages in the parasite’s asexual reproductive cycle. 
Tachyzoites represent the rapidly dividing stage within host cells. Tachyzoites can disseminate to 
multiple and distant tissues within the host’s body and can elicit significant immune responses. 
Although chemotherapeutic drugs and host immune defenses can limit their growth, some tachyzoites, 
have the ability to overcome these formidable challenges and transform into slowly replicating 
bradyzoites. In stark contrast to tachyzoites, bradyzoites divide slowly and remain dormant, protected 
within a stage-specific cyst, mainly located in the brain and muscle (skeletal and cardiac), presumably 
due to less rapid parasite elimination caused by reduced cellular turnover in these tissues compared to 
other organs. The preference of T. gondii to infect neurons, and their particular location within neuronal 
processes, was demonstrated in vivo for the first time by using a T. gondii reporter strain that secretes 
Cre into host cells, which enabled the specific identification and direct visualization of infected neurons 
(8). Bradyzoites are contained within tissue cysts that can evade the host immune responses and 
facilitate the establishment of a long term persistent infection, without causing overt disease (9). A 
recent study identified the Myb-like transcription factor (BFD1) as a key regulator for bradyzoite 
differentiation (10). Infection in humans, commonly occurs via the consumption of food or water 
contaminated with tissue cysts or oocysts (11). Congenital ‘vertical’ transmission also occurs wherein 
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T. gondii tachyzoites are passed from mother to fetus through the placenta (4). Other routes of 
transmission of T. gondii include organ transplantation and blood transfusion (4). 
 
Reproductive Strategies 
According to the established paradigm, the lifecycle of T. gondii involves sexual and asexual 
reproductive phases. The sexual reproductive phase, known as ‘gametogony’, occurs within cats (and 
other felids), which serve as the exclusive ‘definitive’ hosts for T. gondii. In the intestinal epithelium 
of the definitive host, T. gondii differentiates into male and female gametes that form zygotes, which 
leave the cat intestine and are excreted with feces as oocysts (12). This is the main source of genetic 
recombination, should the cat be coinfected with more than one T. gondii strains (13). Infected cats 
shed millions of oocytes for a non-recurring period lasting up to 3 weeks (14). Within 2-3 days 
following excretion, depending on environmental conditions, oocysts undergo maturation/sporulation 
to become infectious. Once they become sporulated, oocysts can survive in the environment and 
maintain their viability for more than a year. The reason that the feline gut epithelium is the only tissue 
that can accommodate sexual reproduction of this parasite remains largely unknown. In recent years, 
interest in the development of methods for establishing in vitro culturing models of cat intestine has 
increased and, it is hoped, that these models may help in unraveling the mechanisms that allow this 
particular location in  this particular host  to support the sexual development of T. gondii (15-17). A 
recent study, using feline intestinal organoids, has shown that a critical factor in the exclusive 
occurrence of sexual reproduction and oocyst production, in the feline gut is the intrinsic abundance of 
linoleic acid in cats when compared to other mammalian (non-felid) hosts (18). Cat’s gut is genetically 
deficient in the enzyme delta-6-desaturase which converts linoleic acid to arachidonic acid. 
Astonishingly, high levels of linoleic acid together with inhibiting delta-6-desaturase that suppresses 
metabolic conversion of linoleic acid to arachidonic acid, have also triggered sexual reproduction and 
oocyst formation in mice (18). Temporal analysis of the transcriptome of cat intestine during the first 
96 hours post T. gondii infection revealed significant changes in transcripts associated with immune 
response and metabolic pathways (19). A recent study showed that sexual differentiation in T. gondii 
can be inhibited by histone deacetylase HDAC3, in a process mediated by microrchidia (MORC) 
protein and the Apetala 2 transcription factor (20).  
T. gondii shows a remarkable diversity in the range of vertebrate species that it uses as intermediate 
hosts. Most warm-blooded mammals, birds and humans can serve as the intermediate host. Although 
humans are permissive to T. gondii infection, they are dead-end hosts, unless they are eaten by a feline 
species. Mammals and birds serve as proper intermediate hosts and transmit tissue cysts to both the 
definitive feline host, and to other intermediate hosts. Within humans and other intermediate hosts, T. 
gondii exists in either the more rapidly proliferating tachyzoite stage or the more dormant bradyzoite 
stage. Ingestion of bradyzoites-containing cysts in raw or poorly cooked meat or infectious oocysts that 
are excreted in felid fecal material are the major infection sources. Upon entry into the small intestine, 
bradyzoites within the cysts, or sporozoites within the sporulated oocysts, are released and invade the 
intestinal epithelial cells where they differentiate into tachyzoites. T. gondii tachyzoites have a 
distinctive ability to migrate to distant body regions including peripheral and immunoprivileged 
regions, such as the eye, brain and placenta. As they invade, tachyzoites produce a membrane-bound 
parasitophorous vacuole (PV). Within this protective shelter, T. gondii tachyzoites secret many effector 
molecules, exploit host cell metabolic resources and reproduce asexually in a process known as 
‘endodyogeny’, whereby each parental tachyzoite divides to form two daughter tachyzoites. This 
reproductive process in the intermediate host continues until the accumulation of newly produced 
tachyzoites causes rupture of the infected cells. Tachyzoites then continue with further rounds of 
invasion and proliferation in new cells. Without therapeutic interventions, or a strong immune response, 
these repeated cycles of intracellular replications will cause severe or even fatal pathologies. In the 
setting of effective immune response or treatment, T. gondii establishes a chronic infection in the 
infected host as bradyzoites inside cysts, surrounded by a wall, formed by modification of the 
membrane, that limits the bradyzoites-containing PV (21). Under certain conditions, T. gondii 
undergoes phenotypic transformation from bradyzoites (the hallmark of latent infection) to tachyzoites 
(associated with acute infection) (22), and this differentiation can lead to adverse, or even life-






Burden, Global Prevalence and Risk Factors of Toxoplasmosis 
As a single disease, toxoplasmosis exerts a significant impact on health-care services, individual 
healthcare costs and health insurance companies. Earlier estimates, published in 2012, suggest that 
toxoplasmosis accounted for nearly $3 billion of illness-related costs, and approximately 11,000 
quality-adjusted life-years (QALYs) lost per year (24, 25). In the USA alone, the total annual incidence 
of toxoplasmosis was estimated to be 9,832; with ocular (2,169) and cerebral (1,399) toxoplasmosis 
being the most prevalent forms of disease (26). Another 11-year study (2000–2010) in the USA reported 
789 toxoplasmosis-related deaths, predominantly in people from Black and Hispanic backgrounds; with 
cumulative productivity losses of approximately $815 million (27). The economic cost of food-borne 
toxoplasmosis in pork was estimated to be $1.9 billion in the USA (28). During 1998-2010, an annual 
average of 20,258 encephalitis-associated hospitalizations (attributed to T. gondii and other infectious 
and non-infectious causes) were reported in the USA (29). A  9-year Canadian study (2002–2011) 
reported an overall annual health-care cost of C$1,686,860 attributed to toxoplasmosis (30). In the 
Netherlands, the toxoplasmosis burden has been estimated to be ~ €44 million in health costs, with the 
loss of 1,900 Disability Adjusted Life Years (DALYs) annually (31). In Denmark, foodborne congenital 
toxoplasmosis was estimated to cause the loss of ~100 years of healthy life in 2017 (32). Estimates of 
the burden of toxoplasmosis in other countries are needed to support country-specific toxoplasmosis 
control planning. 
T. gondii is a highly prevalent parasite in humans worldwide (1). The seroprevalence of T. gondii 
varies substantially between the geographic regions throughout the world. The parasite is particularly 
more prevalent in Western European, South American and African countries (33). The prevalence of 
toxoplasmosis can be seen as a proxy reflecting the hygienic and dietary practices of human populations. 
An increased risk for T. gondii infection has been associated with ingesting raw or under cooked meat, 
particularly pork or lamb meat, or unwashed raw vegetables or fruits. Others factors that can predispose 
an individual to risk of infection, include age, gender, race, educational level, socioeconomic status, 
cultural background, level of health literacy, lifestyle, living in rural areas, proximity to cats, contact 
with soil, scooping cat litter, pregnancy, number of births, frequent travel to endemic areas, 
immigration, quality and source of drinking water, and T. gondii strain genotype/virulence (4, 34). 
Because a cure for the persistent cystic stage is not currently available, latent toxoplasmosis can be 
present for decades, leading to considerable individual and societal burdens. All the aforementioned 
risk factors are, fortunately, readily modifiable, and reducing their impact could potentially reduce the 
prevalence of T. gondii infection. Health-care systems, and current health-management practices, 
should take all the risk factors into consideration so that the burden of toxoplasmosis, particularly in 
certain vulnerable groups or populations, can be minimized. 
 
The Particular Impact On Immunocompromised Populations 
TE is often reported in immunosuppressed people, such as persons living with HIV (PLWH) (23) 
and patients who received hematopoietic stem cell or solid organ transplant (1, 35). Also, patients 
receiving high doses of immunosuppressive chemotherapy or antineoplastic treatment, and patients 
with an underpinning condition, such as cancer, or connective tissue diseases, are at a greater risk of 
toxoplasmosis-associated deaths. In these vulnerable groups, TE imposes a tremendous individual and 
socioeconomic burden. For example in the USA, from 1988 to 1997, toxoplasmosis accounted for over 
21,000 hospitalizations with a mean estimated cost of $28,151 per person attributed to TE-associated 
hospitalization (36). Also, in the USA ~ 3,000 toxoplasmosis-related hospitalizations were reported in 
PLWH in 2008 (37). In Canada, HIV comorbidity with toxoplasmosis was detected in 40% of clinical 
cases between 2002 and 2011, which correlated with  an increased number of hospitalizations and 
treatment cost per case, and accounted for 53% of the total toxoplasmosis-related health-care costs (30). 
In Tanzania, most deaths attributed to toxoplasmosis were highly associated with HIV/AIDS and TE 
was responsible for 15.4% of toxoplasmosis deaths (38). In West Africa, TE accounted for 10% of 
deaths due to AIDS (39). Fortunately, the use of appropriate testing, combination antiretroviral therapy 
(cART) and antimicrobial drugs to prevent opportunistic infection by T. gondii and Pneumocystis 
jirovecii pneumonia,  have significantly helped to reduce the incidence of reactivation of latent infection 
and toxoplasmosis-associated deaths in PLWH (37). Implementation of an early prophylaxis treatment 
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using trimethoprim–sulfamethoxazole (TMP–SMX) starting on the day of engraftment in T. gondii-
seropositive patients, can significantly reduce the rate of parasite reactivation in stem-cell recipients 
(40). 
The findings of a comprehensive review of 72 studies revealed a higher T. gondii infection rate in 
immunocompromised patients vs. control (35.9 vs. 24.7%; p < 0.001), and in PLWH with advanced 
HIV infection vs. control (42.1 vs. 32.0%; p < 0.05), in cancer patients vs. control (26.0 vs 12.1%; p < 
0.001), and in organ transplant recipients vs control (42.1 vs. 34.5%; p > 0.05) (41).  Therefore, 
prevention and treatment of toxoplasmosis should aim to include both HIV and non-HIV 
immunocompromised populations. Emerging epidemiologic evidence based on meta-analysis of 74 
studies, in particular, regarding concurrent infections by T. gondii and HIV from 34 countries revealed 
a worldwide pooled seroprevalence of 35.8%. The prevalence in Asia and the Pacific was 25.1%, sub-
Saharan Africa (44.9%), South American and Caribbean countries (49.1%), and North Africa and 
Middle East (60.7%). As expected, populations in developing countries exhibited higher comorbidity 
(54.7%) compared to those in middle-income (34.2%,) and high-income (26.3%) countries. The 
particularly high burden (87.1%) in sub-Saharan Africa was attributed to the lack of resources, poor 
dietary and sanitary conditions, poor health literacy, limited healthcare capacities and limited access to 
safe water, all of which may have increased odds of infection (42). In these resource-limited settings 
TE can represent a particularly high risk for PLWH patients, particularly those with less than 200 
peripheral blood CD4+ T cells per microliter. A more recent systematic review analyzing 111 studies 
from 37 countries reported a pooled prevalence in PLWH of T. gondii of 44.22% by IgG, which was 
higher than the prevalence obtained based on IgM analysis (3.24%) and molecular methods (26.22%), 
highlighting the high T. gondii infection rate in PLWH (43). The same study also detected a correlation 
between T. gondii positivity and a number of variables, such as gender, consumption of raw meat, 
proximity to cat and awareness of toxoplasmosis, suggesting that risk factors for toxoplasmosis are the 
same regardless of the individual’s immune status. Given that toxoplasmosis results in significant 
illness in immunosuppressed persons, these highly vulnerable groups should be advised by their 
healthcare providers to avoid all behaviors that can put them at risk of serious disease. A greater 
understanding of the levels of T. gondii infection in PLWH, is also important in order to inform policies 





Marching to The Brain  
To cause encephalitis, T. gondii must migrate to and enter the central nervous system (CNS) and 
establish a persistent infection in neural and other brain cells. Following ingestion of the infective stage, 
either oocysts or tissue cysts, the parasite develops into rapidly-proliferating tachyzoites, which invade 
and proliferate within the intestinal epithelium. The tachyzoites then exit and infect dendritic cells 
(DCs) and other immune system cell types, which are important in protecting against T. gondii infection 
(44). These patrolling immune cells are permissive to T. gondii infection and represent an important 
niche for the parasite’s replication. In addition to using immune cells as a replicative niche, T. gondii 
manipulates the functions of these cells to increase their metastatic behavior , which is crucial for the 
dissemination  of T. gondii to distant organs particularly the brain (45). The exact molecular 
mechanisms that promote the hypermigratory behavior of infected cells are not fully, but cellular 
migration seems to depend on chemokines and their receptors. For example, restructuring of the 
cytoskeleton, upregulation of the chemokine receptor CCR7, downregulation of CCR5, increasing the 
secretion of gamma-aminobutyric acid (GABA), induction of GABA-A receptor, and activation of 
calcium channels and calcium signaling, are all implicated in the migration of infected DCs (46-49). 
Additionally, the upregulation of tissue inhibitor of metalloproteinases-1 (TIMP-1), through CD63– 
integrin β1 (ITGB1)–focal adhesion kinase (FAK) signaling promoted the motility of infected DCs 
(50). An increased velocity of infected DCs and microglia was also mediated by the secretory T. gondii 
14-3-3 protein (51). Moreover, the secreted kinase ROP17 promoted the mobility and dissemination of 
T. gondii-infected monocytes (52).  
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Crossing The BBB 
T. gondii spreads to various tissues, such as the eye, heart, liver, lung, lymph nodes, muscles; 
however, this parasite seems to persist in neurons (and muscle) probably due to reduced parasite 
elimination or cellular turnover in these tissues compared to other organs. The parasite’s entry to the 
brain from the blood through cerebral capillary endothelial cells occurs via paracellular transfer into the 
brain following BBB damage, invasion of cerebrovascular endothelial cells allowing transcellular 
transfer, and trafficking within infected immune cells into the brain in so-called ‘Trojan horse’ attack 
(Fig. 1A) (53). The accumulation of cell-free T. gondii tachyzoites at the intercellular junctions prior to 
transmigration indicates that crossing of the BBB can occur via breaching intercellular tight junctions 
(TJs). T. gondii adversely affects the resistance of cerebrovascular endothelial cell monolayers and 
impairs the barrier’s function, thus facilitating paracellular migration (54). Although extracellular 
tachyzoites can overcome the BBB, invasion and replication within brain microvascular endothelium 
is an alternative pathway by which T. gondii enters the CNS (55). Secretion of toxofilin (56) and 
proteases (57) by T. gondii facilitates its traversal of the BBB and may underpin the cellular destruction 
observed along the BBB, when only focal sites are infected by the parasite. Crossing the BBB by T. 
gondii can also occur via exploitation of DCs and monocytes as vehicles for their protection and 
transport across the BBB. T. gondii preferentially enters the brain within parasitized CD11c−CD11b+ 
monocytes and to a lesser extent CD11c+ CD11b+/− DCs. The increased mobilization of T. gondii-
infected phagocytes involves Gi  protein-coupled signalling (57), which promotes diapedesis and 
extravasation of infected cells from cerebral capillaries into the brain. Migration of murine T. gondii-
infected macrophages in Matrigel™ correlates with upregulation of matrix metalloproteinases (MMPs), 
such as MMP-9, MT1-MMP and ADAM10 (58).  
The infiltration of infected cells into such an immune-privileged site as the brain is a highly 
orchestrated process involving interactions with cerebrovascular endothelial cells and is mediated by a 
number of adhesion molecules and chemokine receptors (59). Through activation of the chemokine 
receptor CXCR3, the chemokines CXCL9 and CXCL10 promote the chemotactic recruitment of T cells 
to the brain (60). Through their adhesive function, ICAM-1, and its counterpart VCAM-1, facilitate the 
binding of leukocytes to the cerebrovascular endothelium. The IL-1 signaling stimulates the expression 
of VCAM-1 and ICAM-1 during T. gondii infection in mice  (61). When crossing the BBB, infected 
leukocytes use their LFA-1 integrin to adhere to ICAM-1. Infected leukocytes also use selectin, and its 
glycoprotein ligand, to cross the BBB endothelium. Using antibodies that block the ligand for VCAM-
1 prevents cell entry, further supporting the important role that adhesion molecules  and endothelial cell 
surface receptors have in the influx of myeloid cells, particularly infected monocytes, into the brain 
(62). Interestingly, T. gondii tachyzoites were found in the choroid plexus (CP) of PLWH (63). 
However, the role of the CP and blood-cerebrospinal fluid barrier in the parasite’s entry into the CNS 
is unknown. Collectively, these studies have provided significant insights into the tactics employed by 
T. gondii to cross the BBB in animal models or ex vivo studies. Although our current understanding of 
these mechanisms in humans remain largely speculative, it is logical to assume that T. gondii does not 
cross the BBB via one exclusive mechanism in humans. 
 
What Mediates the Course of a Persistent Brain Infection? 
The preference of T. gondii for neurons is apparent, perhaps because neurons (Fig. 1B), unlike other 
brain cell types, do not react to inflammatory cytokines and thus do not induce a strong antiparasitic 
immune response (64). Although neurons are the main host cell type preferred by T. gondii (8), other 
non-neuronal cell types also contribute to TE (65). Despite continuous immune surveillance, neuronal 
degeneration is rarely observed in immunocompetent hosts infected by T. gondii. This is attributed to 
the effective and balanced proinflammatory (T helper 1 (Th1) antiparasitic) and anti-inflammatory 
(neuroprotective) immune responses. Maintaining this balance is crucial for containing parasite 
proliferation by promoting persistent infection and preventing parasite reactivation, while limiting 
excessive immune pathology.  
Homing of immune cells into the brain. Immune cell migration and extravasation through blood 
vessels, and their homing into infection sites, are important mechanisms for establishing an effective 
immune response. The chemokines and metalloproteinases are key regulators of these events. During 
TE, the cross-talks between chemokines and the cerebral immune response involve CD4+ and CD8+ T 
cells and is mainly mediated by interferon gamma (IFN-γ). Increased production of T cell 
chemoattractants, particularly chemokines CXCL9,  CXCL10 and CCL5, was detected in the brains of 
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mice during latent infection, which was dependent on IFN-γ (66). Infection of astrocytes or microglia 
by T. gondii induced the expression of chemokines CCL5, CCL2, CXCL9 and CXCL10 (Fig. 1C), 
which actively recruit IFN-γ-expressing T cells to control tachyzoite proliferation (59).  
The chemokine receptor CCR2 (and its ligand CCL2) contribute to the migration of monocytes and 
neutrophils into the brain following infection. In CCR2-deficient (CCR2−/−) mice, leukocyte trafficking 
was decreased and immune cells within the brain became less active, leading in turn to an increased 
parasite burden (67). Astrocytes express CCL21 and CXCL10 to promote brain infiltration of CD8+ T 
cells (68) and microglia-derived CXCL10 modulates the search behaviour of CD8+ T cells in a way that 
enhances their ability to detect infection sites in the brain parenchyma (60). The damage signal protein 
IL-33, expressed by oligodendrocytes, induced the expression of monocyte chemoattractant CCL2 by 
astrocytes (Fig. 1B), which is required for the recruitment of monocyte-derived myeloid cells, and the 
expansion of focal myeloid cell-derived inducible nitric oxide synthase (iNOS) - crucial for survival 
during chronic infection (69). T. gondii can also increase the production of the chemokines CCL3 and 
CCL4 in the brain of C57Bl/10 ScSn mice (70) and in cultured cerebellar neurons of mice (64). Infected 
neurons increase the production of the chemotactic macrophage inflammatory protein-1 alpha and beta 
(MIP-1α and MIP-1ß), which have proinflammatory effects, leading to influx of leucocytes at the site 
of inflammation (Fig. 1B). 
The interplay of the TIMP-1 and MMPs also influences the infiltration of T cells and parasite control 
(Fig. 1D). Astrocytes infected with T. gondii produced MMP-2 and MMP-9, possibly to increase 
extravasation and infiltration of inflammatory cells to the infection sites (71). In a mouse model, MMP-
8 increased infiltration of CD4+/CD8+ T cells and MMP-10 increased infiltration of CD4+ T cells into 
the brain. TIMP-1 in astrocytes and in the infiltrating CD4+/CD8+ T cells decreased the brain parasite 
load, without the development of adverse pathology. An increase in CD4+ T cells and a significant 
reduction in parasite load were detected in the brain of mice deficient in TIMP-1 when compared to 
wild type (WT) controls, without substantial brain injury nor any reduction in the peripheral parasite 
burden (72). This suggests that production of TIMP-1 may be an attempt by astrocytes to block parasite 
elimination by restricting MMP-mediated recruitment of lymphocytes. This scenario seems to favour 
parasite survival and to restrict neuroinflammation and brain damage, which ultimately promotes 
persistent infection. 
The roles of cytokines in containing infection. Following brain invasion, T. gondii tachyzoites 
encounter strong cell-mediated (type 1) immune responses marked by the production of IFN-γ, 
interleukin [IL]-12 and tumor necrosis factor-α (TNF-α), which clear most of the invading tachyzoites 
(73). T. gondii infection induces the expression of Toll-like receptor (TLR) 11  in astrocytes, neurons, 
and microglia in mice (74). TLR11 stimulation by parasite’s profilin protein induces IL-12 in DCs (75). 
MyD88 knockout mice rapidly succumbed to acute infection, with a commensurate impairment in IL-
12 response - suggesting that mice resistance to toxoplasmosis depends on MyD88-dependent signals 
regulated by TLRs (76). Many in vitro and in vivo studies have indicated the fundamental role that IFN-
γ plays in protecting the host from severe T. gondii infection. IFN-γ controls parasite replication via 
various mechanisms, such as stimulating the degradation of the PV via the production of immunity-
related GTPases (IRGs) and interferon-inducible guanylate-binding proteins (GBPs), increasing 
expression of major histocompatibility complex (MHC) and induction of iNOS and the 
immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO) (77-80). Production of NO by iNOS 
inhibited T. gondii proliferation within macrophages in vitro (81) and in mouse brain (82). The 
procurement of nutrients, such as tryptophan, from the host cells is essential for intracellular T. gondii 
survival. Hence, the breakdown of tryptophan into kynurenine due to IFN-γ-mediated IDO induction 
can result in inhibition of tachyzoite growth (83). Increased kynurenic acid concentrations during 
infection acts as an agonist of the immunosuppressive aryl hydrocarbon receptor (AhR), which results 
in controlling the pathological immune response associated with toxoplasmosis. Mice deficient in AhR 
(AhR−/−) succumbed more readily to illness, but developed fewer brain cysts than WT mice infected by 
T. gondii (84). Additionally, the excessive production of kynurenic acid, which blocks the alpha-7 
nicotinic acetylcholine receptor (α7 nAChR) and disrupts other neuroreceptors in infected astrocytes 
and microglia can lead to abnormal neurotransmission (85), and was hypothesized to lead to cognitive 
dysfunction (Fig. 1C). In response, T. gondii secretes TgIST, an inhibitor of signal transducer and 
activator of transcription 1 (STAT1) transcriptional activity, which antagonizes IFN-γ-induced IDO1-
induced immunity against T. gondii in human cells (86). Mice deficient in the lymphotoxin-β receptor 
(LTβR), which has diverse antimicrobial immunoregulatory roles, had a higher parasite burden and 
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increased mortality in acute T. gondii infection than immune competent control mice. The impaired 
resistance of LTβR−/− mice was attributed to the deregulation of interferons and interleukins, as well as 
a reduced upregulation of murine GBP, which is mediated by IFN-γ and is crucial for parasite 
elimination - further supporting the importance of IFN-γ in controlling T. gondii (87). Mice lacking 
mGBP7 failed to control parasite replication and succumbed to acute infection (88).  
The contribution of astrocytes and microglia to the pathogenesis of TE is notable. Inhibition of T. 
gondii replication in astrocytes was attributed to an increased induction of IFN-γ–induced GTPase 
(IGTP) (89). Genetic deletion of STAT1 in astrocytes promoted the spread of T. gondii infection and 
increased susceptibility to TE (90). The orphan nuclear hormone receptor TLX, expressed in astrocytes 
and neural stem cells can support resistance to T. gondii through enhancing STAT1 activity (91). Mice 
lacking cytokine receptor gp130 (a protein of IL-6 signalling pathway) in astrocytes showed increased 
astrocyte apoptosis and inflammation during T. gondii infection. Although these mice were able to 
control parasite numbers, they developed excessive inflammation and succumbed more easily to rapid 
development of TE (92). Interestingly, microglia did not seem to be the only cells in charge of 
controlling T. gondii in the brain through T cell-derived IFN-γ mechanisms. Mice in which both 
monocyte-derived macrophages and microglia were made deficient in IFN-γ signalling, succumbed to 
infection by 19 days post infection. Conversely, mice in which microglia were only deficient in IFN-γ 
signalling, were able to resist infection (93). Interestingly, a recent study using a microglia reporter 
mouse model showed that microglia can promote neuroinflammation via the release of alarmin IL-1α, 
which recruits more immune cells to control chronic brain infection (61). 
The cysticidal role of CD8+ cytotoxic T lymphocytes (CTLs). The anti-cyst activity of CD8+ 
CTLs and the control of TE are mediated by mechanisms that utilize both the IFN-γ (the key effector 
of protective immunity against tachyzoites) and perforin-mediated immune responses (94).  Control of 
brain cyst burden is mediated largely by CD8+ CTLs that produce perforin and M2 microglia expressing 
CXCR3, acidic mammalian chitinase (AMCase) and arginase-1 (95, 96). Although M2-like microglia 
populations act to inhibit neuroinflammation, AMCase-deficient mice can develop a high parasite 
burden in the brain, indicating a role for M2-like microglia in controlling the parasite cysts. Both 
perforin and granzyme B underpin the capacity of CD8+ CTLs for direct invasion and elimination of 
the existing T. gondii cysts (97). Adoptive transfer of perforin-competent CD8+ CTLs to 
immunodeficient mice significantly reduced cyst load and increased the level of CXCR3 and CXCR6, 
which promote the recruitment of microglia and macrophages to destroy bradyzoites within T cell-
attacked cysts (98). The induction of the CD8+ CTLs responses is also mediated by rhoptry protein 
ROP7 and dense granule protein GRA6 (99, 100). The cysticidal capacity of CD8+ CTLs is related to 
the amino-terminal region of T. gondii GRA6 (GRA6Nt) (101). Markedly, one epitope in the C-terminal 
region of GRA6 was a strong inducer of IFN-γ-mediated protection against acute toxoplasmosis in mice 
(99). These results suggest that host immune responses can recognize different GRA6 regions to 
stimulate CD8+ T cell-based protection against both tachyzoites and tissue cysts. The cysticidal 
mechanism is initiated by CD8+ CTLs, but the removal of cysts is accomplished by microglia and 
macrophages, which  invade the cysts and destroy the bradyzoites (95). INOS-mediated protection 
conferred by CD8+ CTLs is important for inhibiting the development of toxoplasmic cysts; but does not 
play a role in the mechanism required to eradicate the cysts (102).  
Immune evasion strategies. T. gondii is an exceptionally successful intracellular parasite.  Despite 
being at constant risk of a sustained and efficient immune defensive patrol, it can linger inside the body 
of the host for a long time. Some tachyzoites can escape destruction from the immune response (or from 
drugs used to treat toxoplasmosis) and transform into bradyzoites inside quiescent cysts. Paradoxically, 
the Th1-polarized immune response essential for eradication of acute infection is the same response 
required to develop latent infection in the brain. T. gondii seems to subvert CD4+-mediated immune 
responses through the inhibition of the MHC II transactivator CIITA, which contributes to its long-term 
survival in the brain (103). T. gondii also produces cyclophilin‐18 mimicking chemokine, which, when 
bound to CCR5 on DCs, evokes a Th1 response (e.g. production of IL‐12), required for the 
establishment of persistent infections (104). The expansion and functional maturation of cerebral DCs 
contributes to the development of latent infection (105). T. gondii possesses secretory organelles that 
discharge a number of polymorphic effector proteins that seem spatially and temporally controlled, as 
different effectors are secreted at different stages of host cell invasion and colonization; and effector 
secretion is targeted to specific locations to selectively modulate a specific function or a regulatory 
pathway within the host cell (106-108). These effectors are utilized by T. gondii to circumvent host 
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immunity, and to support the establishment of a latent infection (109). For example, GRA23 and 
GRA17 control the delivery of small metabolites to the PV and promotes the structural stability of the 
PV (110). More recently, GRA17 and GRA23 have been shown to mediate the growth, virulence, cyst 
burden, and immunogenicity of the type II PRU strain (111). GRA39 contributes to parasite virulence 
and tissue cyst burden (108). Additionally, ROP16 serves as a virulence factor that activates STAT3 
and STAT6 and inhibits T cell responses (112). ROP5 forms a complex with ROP17 and ROP18 to 
prevent the recruitment of IFN-γ–mediated IRGs, which are essential for PV destruction and parasite 
control (113). In addition to inhibiting STAT1 transcriptional activity (86), TgIST binds to the 
STAT1/STAT2 heterodimer, leading to the inhibition of type I IFN pathway (114). 
Striking a balance between friend and foe. The long-term presence of dormant cysts in the host 
tissues requires a well-coordinated immune arsenal that is sufficiently potent to combat the infection, 
yet moderate enough to counterbalance hyperinflammation. Mice deficient in 5-lipoxygenase (5-LO) 
(115) or suppressor of cytokine signaling (SOCS)-2 (116), succumbed to chronic infection and showed 
increased mortality due to excessive inflammation caused by elevated IL-12 and IFN-γ, regardless of 
the reduction in the brain cysts. Therefore, the effects of  proinflammatory cytokines (e.g. IFN-γ)  must 
be buffered by immunosuppressive effectors (IL-27, IL-10, TGF-β) and receptors (e.g. PD-1, LAG3, 
TIGIT), without which continued secretion of inflammatory cytokines and homing of T cells into the 
brain can lead to an exaggerated inflammatory response and encephalitis (117, 118). Therefore, the 
relative balance between IL-10 and IFN-γ produced by T cells will dictate whether the immune response 
will eliminate the parasite with limited immunopathology or whether chronic infection will be 
established. Regulatory T cells (Tregs) are activated by IL-27, secreted  by monocytes, to induce IL-10 
and T-box transcription factor (T-bet) expression to attenuate the inflammatory responses (119). In the 
absence of IL-27, T. gondii increases the levels of IL-17 and GM-CSF and results in neuroinflammation 
in mice (118). The reduction of IL-10, by blocking the IL-10 receptor in chronically infected mice led 
to significant tissue destruction due to the extensive inflammatory response in the brain. The anti-
inflammatory role of IL-10 during toxoplasmosis is also evidenced by the fact that mice lacking IL-10 
succumbed to fatal CNS inflammation (120, 121). Deletion of the transcription factor Bhlhe40, an IL-
10 repressor, resulted in severe T. gondii infection in mice, which was attributed to reduced IFN-γ and 
increased IL-10 production  (122). 
Although the IL-10, which is commonly produced by Th2 cells, has broad anti-inflammatory 
properties, and suppresses Th1-cell pro-inflammatory responses (123) via its inhibitory effect on the 
function of macrophages and DCs (124), Th1 cells secreting IL-10- and IFN-γ were detected in animals 
infected by T. gondii (125, 126). Recent studies have identified a number of immune cells (for example  
B cells, eosinophils, and CD8+ CTLs, Tregs and antigen-driven regulatory CD4+ T cells), which can 
produce IL-10 (127). Tregs expressing CXCR3 were also found to express T-bet and Foxp3, and secrete 
IFN-γ and IL-10. It remains to be completely defined how IL-10 functions to limit tissue damage, while 
at the same time it promotes persistent infection. More research is required to reveal the extent of 
dependence between the mechanisms used by different types of cells to secrete IL-10 and to elucidate 
how and to what magnitude different sources of IL-10 execute the aforementioned distinct activities.  
TGF-β signaling in astrocytes is of particular interest for its immunosuppressive role during brain 
injury (128). Infected astrocytes secrete prostaglandin E2 (PGE2) to activate microglia which suppress 
nitric oxide (NO) production  (129). TGFβ-1 plays a role in the inhibition of iNOS and NO production 
by IFN-γ-activated microglia (130). TGF-β signaling in astrocytes controls neuroinflammation and 
neuronal injury, via the inhibition of NF-κB signaling which, in turn, inhibits CCL5 and the infiltration 
of T cells and macrophages (131). Thus, lack of a TGF-β signaling in astrocytes, while not necessarily 
affecting parasite burden, can increase inflammation and neuronal damage.  
The role of Tregs in TE. The role of Tregs in toxoplasmosis has yet to be fully understood. 
However, elucidating of the mechanisms that underpin Tregs’ interaction with CD11c-expressing DCs 
in the meninges and perivascular space is warranted (132). Reduction of the suppressive Tregs during 
acute toxoplasmosis is commensurate with increased IFN-γ in an IL-10–independent/IL-2–dependent  
manner (133). In TE, Tregs expressing Th1 response-related molecules, such as T-bet, and CXCR3, 
and IFN-γ, were detected in the brain,  probably to limit neuro-inflammation via IFN-γ-mediated 
increased IDO expression (134). Studies in KO mice have shown that ICOS signaling promotes 
inflammation and antibody production - both being important for parasite control - while helping to 
control inflammation by inhibiting effector T cell proliferation and inducing Tregs in the brain and 
spleen (135), or by inducing IL-10 production in T cells (136).  
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What makes the murine model different from humans? Our knowledge of the pathophysiology 
of toxoplasmosis has mostly been derived from studies in mice, and must be interpreted with caution. 
Marked differences exist between murine models and humans and their mechanisms of innate 
recognition and cytokine production. For example, IFN-γ-mediated IRGs’ and GBPs’ immune 
responses in mice does not seem to have an equivalent in humans (106). Furthermore, parasite 
recognition and the initiation of innate immunity in mice, requires stimulation of TLR11 and TLR12 
by the parasite profilin for the production of cytokines by myeloid cells (75, 137). The role of  
TLR11/TLR12 in recognizing the parasite profilin in mice is absent in humans; instead, immune 
recognition triggered by phagocytosis of the live parasite leads to IL-12 being produced by myeloid 
cells (138). In contrast, immune cells in mice do not require direct contact with live tachyzoites (139). 
Human peripheral blood mononuclear cells can produce IL-12 and TNF-α after stimulation with T. 
gondii nucleic acids, suggesting the involvement of TLRs 7, 8, and 9, all of which function  to recognize 
foreign nucleic acids (140). A recent study using human monocytes, has shown that the recognition 
pathway for T. gondii relies on the detection of S100A11, a damage-related molecule secreted from 
adjacent infected cells (141). Taken together, these results indicate that recognition of the pathogen is 
not a prerequisite for the induction of an anti-T. gondii immune response, because immunity in humans 
and mice can also arise from sensing active infection. Additional differences include the production of 
large amounts of IL-12 from mouse DCs, whereas the human response to T. gondii mainly involves the 
expression of CCL2 (141). In mice T. gondii induces the production of  IL-12 by myeloid cCD2 cells 
(e.g. CD8α+), which are distinct from the IL-12-producing cDC1 subset (e.g. CD1c+) in humans (138). 
Differences in cytokine production also exist between human and murine subpopulations of monocytes 
in response to T. gondii stimulation (138). Despite the aforementioned differences, mice remain an 
important model for the investigation of T. gondii infection, and for the development of remedial 
measures. Work towards developing animal models continues, as illustrated by a recent report using 
Zebrafish as a model to study T. gondii replication, T. gondii strain-specific variations in host response 
and interaction with immune cells (142). 
 
Reactivation of Latent Infection 
Dormant tissue cysts encapsulating slow-growing bradyzoites are fundamental for the long-term 
survival and persistence in the host’s brain, due to their ability to evade immune-mediated destruction. 
The question arises: what advantage does T. gondii gain by undergoing phenotypic transformation from 
dormant bradyzoites protected within cysts, to the more active tachyzoites - which are less able to 
counter host immune responses? Some studies provide direct evidence supporting a link between 
immunosuppression and reactivation of latent infection. Indeed, parasite cyst reactivation is a high-
frequency occurrence in immunocompromised people - such as individuals who received organ 
transplantation and PLWH who have AIDS, in particular those who are not on cART, and are not 
receiving prophylactic TMP–SMX (23, 143, 144). In these groups of patients, phenotypic switching 
provides opportunity for uncontrolled proliferation of tachyzoites in excessive numbers which can 
overwhelm the capacity of the host’s already-compromised immune system, resulting in life-
threatening consequences (53). Therefore, durable cell-mediated immunity to T. gondii is essential for 
protecting the host from reactivation of any latent infection. It remains to be shown whether immune 
suppression triggers reactivation; or if reactivation continues at a set rate and the immune system, which 
would normally control any tachyzoites that are released, is suppressed allowing replication without 
control leading to a clinical reactivation.  
As stated above, IFN-γ has a crucial role in the control of latent infection (73, 145). Microglia are 
a further source of IFN-γ production, and contribute to the protective immune response that maintains 
the CNS tolerance to T. gondii presence, and prevents any recrudescence of latent cerebral infection 
(146). The production of IFN-γ in microglia is mediated by the N-terminus region of GRA6 (GRA6Nt), 
which likely serves as a warning signal for neighboring uninfected microglia of the parasite’s presence. 
This would be a preemptive strategy to limit any further growth of tachyzoites in the brain via activation 
of the protective immune responses, and increasing microglial production of IFN-γ (147). Astrocytic 
TGF-β signaling exerts an anti-inflammatory and neuroprotective functions during T. gondii infection 
(131). Astrocyte dysfunction during HIV can, therefore, lead to loss of their protective roles and 
diminish their ability to counter infection (131). CXCL9 recruits and accumulates T cells around the 
parasite-infected brain areas to prevent any reactivation of latent cerebral infection (148). The influx of 
T cells into the brain is also mediated by the action of IFN-γ on the cerebrovascular endothelium;  IFN-
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γ increases VCAM-1/α4β1 integrin interactions, which appears to serve as a host defense mechanism 
during the early reactivation of dormant cysts, to suppress TE (149, 150). 
Pharmacological agents, through their anti-parasitic or immunomodulatory effect can also modulate 
the reactivation of latent cysts and the development of TE. For example, termination of sulfadiazine 
treatment resulted in reactivation of latent infection in a murine model (151). The use of biological 
agents, such as anti-α4 integrin monoclonal antibodies used in the treatment of Crohn's disease or 
multiple sclerosis can interfere with the VCAM-1/α4β1 integrin interaction and brain homing of CD4+ 
and CD8+ cells, potentially increasing the odds of reactivation of latent toxoplasmosis (Fig. 1E).  In line 
with this assumption, administration of anti-α4 integrin antibody inhibited key factors that play roles in 
controlling T. gondii growth, such as iNOS, T cells and IFN-γ in the mouse brain (150). In addition to 
taking into account the effect of using immune-modulatory biologics on the reactivation of tissue cysts, 
the impact of secondary/opportunistic infections in chronically infected patients should be also 
considered. The interaction between T. gondii and HIV is just one example. While HIV-induced 
impairment in immune response triggers reactivation of dormant cysts, coinfection with T. gondii 
compromises host immune defenses to HIV-1 and HSV-1 by suppressing plasmacytoid dendritic cell 
(pDC) activation and inhibition of IFN-α production (152). During latent toxoplasmosis, exhaustion of 
CD8+ CTLs and induction of programmed cell death 1 (PD-1) rendered CD8+ CTLs liable to destruction 
via apoptosis, leading to reactivation of latent infection and host mortality (153, 154). Blocking PD-1 
and its ligands PD-L1 has a potential therapeutic value as anti-PDL-1 treatment reinvigorated CD8+ 
CTL’s response, which prevented reactivation of tissue cysts and improved survival of chronically 
infected mice (153). Also, inhibition of PD-1–PD-L1 pathway can decrease expression of  caspase 3 on 
polyfunctional and IFN-γ+/granzyme B− memory CD8+ CTLs in vitro (154). Additionally, blockade of 
immune checkpoint inhibitor PD-1 significantly reduced brain cyst burden and increased brain 
infiltration of  CD8+ CTLs, CD11b+ DCs and CD3+ T cells in mice (155). All the afore-mentioned 
studies indicate that development of strategies to prevent T. gondii reactivation is achievable by 
maintaining enhanced proinflammatory effectors without disproportionate reduction of the anti-
inflammatory mediators. 
 
CLINICAL SIGNS AND DIAGNOSIS 
Infection of the CNS with T. gondii, or TE, can cause severe illness and death in 
immunocompromised individuals. The worldwide T. gondii seroprevalence in PLWH ranges from 
~26% in high income countries to ~55% in low income countries (42). The risk factors for TE in PLWH 
include blood CD4+ T cells less than 200/µl, lack of TMP–SMX prophylaxis, which may be given to 
specifically prevent TE or Pneumocystis jiroveci pneumonia (143, 156), and lack of cART used to 
control HIV infection (23, 144). Because the greatest current experience with TE is in PLWH, and 
clinical guidelines are available (157), we focus on this risk group. However, the principles used in the 
diagnosis, screening and prevention of TE in PLWH are applicable to other at-risk populations.  
 
Clinical Features 
TE most commonly presents as a single, or more commonly, multiple brain abscesses with a 
predilection for the deep gray matter structures or the junction between cortical gray and white matter. 
However, any part of the brain can be affected. As such, neurological abnormalities can be similar to 
what might be seen in an individual with one or multiple brain lesions from any cause. More unique to 
TE is fever. Commonly described neurological abnormalities in PLWH with TE are subacute onset of 
headache, hemiparesis, cranial nerve palsies, ataxia, change in level of consciousness or seizures (158, 
159). Due to involvement of the basal ganglia, abnormal movements, including chorea and ballism, and 
rigidity may also be observed (158, 160). Uncommonly, patients may present with an encephalitic 
illness rather than discrete brain abscesses. These individuals may present with fever, meningeal signs, 
such as headache, stiff neck and photophobia, and encephalopathy that is rapidly fatal (161, 162). 
Similar clinical manifestations and course have been reported in people with necrotizing ventriculitis 
due to T. gondii (163). 
 
Diagnostic Tests 
Serological diagnosis. The Sabin Feldman Dye Test, first reported in 1948, remains the “gold 
standard” for serological detection of anti-Toxoplasma IgG and IgM antibodies (164). However, this 
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method requires using live tachyzoites, which is not feasible in most laboratories. Enzyme-linked 
immunosorbent assay (ELISA) is commonly used to detect specific IgG and IgM antibodies against T. 
gondii. IgG titers peak within 1-2 months post infection, and stay high for life, which is why they are a 
good marker of risk for TE in PLWH, which almost always occurs following reactivation of a pre-
existing latent infection. Because the proportion of PLWH with TE who have serum anti-T. gondii IgG 
antibodies can reach 100% (165, 166), identification of PLWH who are IgG seropositive identifies those 
at risk for the disease. However, empiric diagnosis based on IgG level can be misleading because 
elevated serum anti-T. gondii IgG titers are common in the general population, even in the absence of 
active illness (167). An avidity assay, which is a modification of the ELISA, incorporates a denaturing 
agent (e.g. urea) within serum dilutions to test for antibody avidity. The avidity values are lower during 
acute infection and increase over time, which can be used to estimate when seroconversion has 
occurred, and are useful in the evaluation of reactivated infection and in pregnant women who acquire 
infection during gestation (168). IgM antibodies can be detectable for over a year. Thus, the presence 
of IgM antibodies does not necessarily indicate a recent infection, however, the lack of IgM rules out 
recent infection. Perhaps unexpectedly, PLWH with TE do not mount an IgM response. 
Cerebrospinal fluid (CSF) analysis. Mild mononuclear pleocytosis and elevated protein can be 
detected in the CSF of patients with TE. Diagnostic tests for detection of toxoplasmosis-specific IgG 
and IgM antibodies in the CSF do not have proven utility beyond an empiric treatment trial. The 
detection of T. gondii DNA in CSF using polymerase chain reaction is specific, but not sensitive, for 
diagnosis of TE (169, 170), meaning that a positive test confirms the diagnosis, but a negative test does 
not rule it out. Diagnostic accuracy decreases if CSF is examined after more than a week of TE therapy 
(170). In a PLWH with a focal brain lesion with mass effect who is not receiving anti-Toxoplasma 
prophylaxis, detection of T. gondii DNA in CSF increases the likelihood of TE from 87% to 96% (171). 
It is important to remember that lumbar puncture for collection of CSF may not be safe in TE due to 
mass effect, which increases the risk of brain herniation after lumbar puncture. 
Histopathology. CNS toxoplasmosis in PLWH can lead to granulomatous reactions with gliosis 
and microglial nodules and  necrotizing encephalitis (172). The detection of tachyzoites either alone or 
together with tissue cysts is diagnostic. Immunohistochemistry can improve the detection and 
localization of the parasite (173).  
Neuroimaging. Brain imaging is particularly useful for the diagnosis and management of patients 
with TE. Brain examination using computed tomography (CT) scan revealed hypodense and contrast-
enhancing focal brain lesions with mass effect, primarily in basal ganglia, thalami, and cortico-
medullary junction in 70-80% of PLWH with TE.  Less often, TE in PLWH presents with one lesion 
or with no lesions on brain CT. Rarely, ventriculitis can be seen on brain CT of PLWH with TE (163, 
174, 175). Magnetic resonance imaging (MRI) is the clinical imaging standard used  in PLWH with 
suspected TE (176, 177). Given the better sensitivity of MRI compared to CT, often patients with one 
lesion or no lesions on CT may have multiple lesions detectable by MRI (Fig. 2). Concentric and 
eccentric “target sign” enhancement on contrast enhanced MR images has been described (178, 179). 
Although TE can occasionally cause a single brain lesion on MRI, an alternative diagnosis, such as 
primary CNS lymphoma, should be considered in these individuals (180). Both TE and primary CNS 
lymphoma can cause contrast-enhancing lesions with mass effect and thus cannot be easily 
differentiated based on neuroradiologic criteria. However, the presence of hyper-attenuation on non-
enhanced brain CT and subependymal location are more specific for lymphoma (181). Based on the 
retention of thallium-201, using single-photon emission computed tomography ([201Tl]-SPECT) 
imaging can reliably differentiate CNS lymphoma (uptake) from TE (no uptake). Indeed, SPECT 
demonstrated a 92% sensitivity and 85% specificity in distinguishing CNS lymphoma from other focal 
brain lesions in PLWH (182). The use of cART may decrease the specificity of SPECT in distinguishing 
between the two diagnoses (183).  
 
How Clinicians Use Laboratory Tests in Their Diagnostic Algorithms 
In PLWH, the differential diagnosis for those with brain mass lesions with contrast enhancement 
and mass effect includes most commonly TE, primary CNS lymphoma and tuberculoma or tuberculous 
abscess (Table 1). Individuals who are seropositive for anti-Toxoplasma IgG, have blood CD4+ T cells 
< 200/µl, and are not receiving prophylaxis for TE have a high likelihood of TE (23, 184-186), and the 
approach to these individuals is an empiric treatment trial. As noted above, a positive CSF PCR for T. 
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gondii further increases the likelihood of TE to above 90% (171), but lumbar puncture for collection of 
CSF is often not safe in patients with mass lesions. Clinical and radiographic improvement after 10-14 
days of empiric treatment for TE is used to establish the diagnosis. Although brain biopsy is the gold-
standard for diagnosis (187), it is reserved for patients with low probability of TE, for example those 
who are seronegative, and for individuals who fail to respond to a treatment trial (188). Accurate 
identification of TE can be challenging in individuals who do not have HIV, including recipients of 
hematopoietic stem cell or solid organ transplants, and those who received immunomodulatory 
therapies, in whom a wide variety of bacterial and fungal pathogens are possible. An example of this 
challenge is an individual with multiple sclerosis (MS) who developed TE during treatment with 
fingolimod (189). Brain lesions resembled tumefactive MS and prompted intensification of MS 





Parasite dormancy exhibited by the cystic stage remains the main stumbling block to achieve 
effective eradication of toxoplasmosis because no drugs can clear tissue cysts of T. gondii (190).  
Current treatments can only manage acute and reactivated infections; both are caused by tachyzoites. If 
treatment is delayed, mortality can reach a very high level in immunocompromised individuals. The 
activity of pyrimethamine (PYR) is potentiated when combined with sulfadiazine (SDZ) or clindamycin 
(CLD) for TE in PLWH (191, 192) and, in combination with folinic acid,  is the recommended initial 
treatment (193). High dose TMP-SMX is an alternative when the preferred regimen is not available 
(194, 195). Owing to the potential allergy or toxicity that can occur with the use of these drugs, 
alternative regimens have been used in PLWH, including the macrolide antibiotic azithromycin or 
antimalarial agent atovaquone. Unfortunately, limited access to first-line drugs for acute TE may oblige 
physicians to choose an alternative therapy. A lower-priced PYR oral suspension successfully 
controlled TE in a PLWH (196), providing a new solution to tackle the challenge of affordability of the 
PYR-based regimen. While the aim of the study is laudable, it highlights concerns beyond issues of 
efficacy and safety, such as rising drug prices, industry profits, and patient access to crucial drugs, 
especially uninsured patients. More information about the treatment of toxoplasmosis in 
immunocompromised patients can be found in other reviews (195, 197). 
 
Prevention 
Over the past few decades, knowledge of T. gondii biology, epidemiology and ecology has 
expanded exponentially and has provided the underpinning of the measures currently used to control T. 
gondii infection. Preventative measures focus on limiting the contact with known routes of transmission 
and reducing exposure to the parasite’s infective stages. As mentioned above, humans acquire T. gondii 
by consuming food or water contaminated with oocysts shed in cat feces or by ingesting the parasite 
cysts in raw or undercooked meat. Also, acquisition of infection can occur via ingestion of raw shellfish 
(198). Therefore, PLWH who are seronegative should only eat meat that has been thoroughly cooked, 
avoid eating raw shellfish, thoroughly clean their hands following touching raw meat, avoid gardening 
or handling soil without gloves, and eat fruits and vegetables that are properly washed. If PLWH have 
a cat, daily changing of the litter box should be delegated to another person who is not 
immunocompromised and non-pregnant. Wearing disposable gloves and washing hands thoroughly 
with antiseptic should be a common practice for individuals who manage the litter box. When possible, 
cats should stay indoors and not be fed raw or undercooked meat, and seronegative PLWH should not 
adopt or handle stray cats. The above recommendations for prevention of T. gondii infection are also 
applicable to individuals in other specific at-risk groups. Standardized guidelines recommend that all 
PLWH be tested for serological evidence of previous T. gondii infection soon after HIV diagnosis (157). 
PLWH who are also seropositive for T. gondii with peripheral blood CD4+ T cells <100/µl should 
receive primary prophylaxis to prevent TE (157). Individuals treated with cART who have more than 
200 CD4+ T cells/µl for > 3 months can safely discontinue primary prophylaxis. PLWH who have been 
successfully treated for TE and are receiving cART can discontinue maintenance treatment when they 
achieve more than 200 CD4+ T cells/µl for > 6 months (157). It is worth noting that despite these 




QUALITY OF LIFE  
 
Link to Psychiatric Illness and Cognitive Function  
Interest in exploring the connection between infection and behavioral alterations and brain illnesses 
in humans was sparked following the discovery that T. gondii can induce neurologic changes in its 
intermediate murine hosts in order to make them easier prey for the definitive feline host (199). Despite  
a considerable amount of data, evidence surrounding the impact of T. gondii on neurological functions 
particularly in regard to behavioral modifications and neurodegenerative disease remains conflicting 
(200). There is serological evidence, albeit indirect and preliminary, pointing to an association between 
T. gondii infection and psychiatric abnormalities, such as schizophrenia and bipolar disorder (201-203). 
However, randomized clinical trials of toxoplasmosis treatment have not shown a benefit in individuals 
with schizophrenia (204). Also, correlations between serological evidence of T. gondii infection and 
poorer neurocognitive function has been reported in some, but not all, studies, including in PLWH (205, 
206). Cognitive impairment in individuals with schizophrenia who are also T. gondii seropositive was 
attributed to immune-inflammation mediated by alterations of kynurenine metabolism (207, 208). T. 
gondii can also alter other pathways, such as dopaminergic and GABAergic pathways, which have also 
been implicated in the neurobiology of schizophrenia (209). To what extent T. gondii-related alterations 
of the aforementioned pathways lead to psychiatric illness and cognitive impairment remains to be 
clarified. 
 
Prognosis of TE in PLWH 
More than half of PLWH who survive TE have residual neurological abnormalities (210). In 
addition, they are faced with the possibility of HIV progression and cognitive impairment. A 
prospective study of 205 PLWH and TE showed that initiation of cART within 2 months of TE 
diagnosis reduced HIV disease progression compared to those who started cART after two months (23). 
These results are consistent with studies that have shown improved survival of PLWH who develop TE 
in the cART era (210). PLWH with prior TE may be at greater risk of subsequent cognitive impairment 
and dementia compared to those with other CNS or non-CNS opportunistic infections (211, 212). 
 
 
PROGRESS, CHALLENGES AND FUTURE PROSPECTS 
 
New Pharmacological Targets 
As mentioned above, PYR and SDZ are the drug of choice. This drug combination synergistically 
inhibits dihydropteroate synthase and dihydrofolate reductase, both play key roles in folate 
biosynthesis, which is essential for the growth and proliferation of T. gondii  (213). Other treatment 
regimens involve atovaquone, which exerts its effect by inhibiting the mitochondrial cytochrome bc1, 
leading to interruption of cellular respiration and suppression of the parasite growth (214). Clindamycin 
exerts its antimicrobial activity via inhibiting protein synthesis in the apicoplast, a vestigial plastid 
organelle presents in T. gondii and other protozoa in the phylum Apicomplexa (215). Intolerance, poor 
absorption (191), variations in the susceptibility of T. gondii strains to PYR (216), increased pricing 
(196), and adverse dermatologic and hematologic reactions associated with the use of PYR-based 
therapy (194), and inability to kill bradyzoites (190), are major challenges that limit the effectiveness 
of the current first-line interventions. For these reasons, there have been significant interests in the 
discovery of new formulations to treat TE. An earlier study showed that atovaquone nanosuspensions 
have improved bioavailability and high therapeutic efficacy against reactivated toxoplasmosis in mice 
(151). Another study demonstrated that treatment of mice with sodium dodecyl sulfate-coated 
atovaquone nanosuspensions reduced parasite load and inflammatory reactions in the brain (217). 
The last few decades have witnessed significant progress towards exploring novel and better 
therapeutic agents for TE. Parasite-targeted therapeutics has been the most common approach used to 
discover new generations of anti-T. gondii drugs. This approach involves in vitro high throughput 
screening of libraries of compounds for identification of those novel molecules with a potent 
toxoplasmicidal activity at nanomolar concentrations against the tachyzoite and/or bradyzoite stage. 
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The clinical benefit of this approach is limited owing to the need to understand the compound’s toxicity 
and potential side effects, mode of action, and pharmacokinetics. Addressing these issues can be costly 
and time consuming. An alternative strategy to overcome these hurdles is to test compounds approved 
to treat other indications (218). Drug repurposing has the added advantage of discovering new leads 
with novel scaffolds (different from the scaffold of PYR) and exhibit novel mechanism of actions. 
Screening molecules in the open access Malaria Box (i.e. Medicines for Malaria Venture) has revealed 
new anti-T. gondii drug candidates that seem to hold a promising therapeutic potential (219, 220). 
Encouraging results have been reported in other repurposing screens of existing drugs where several 
compounds were found to have a new anti-T. gondii indication (218, 221). 
 
Tackling The Treatment Impasse of Latent Infection 
Elimination of persistent T. gondii cysts is a prerequisite for the success of any prophylactic program 
that aims to eliminate the risk of TE in vulnerable populations. As noted above, researchers have tested 
the efficacies of repurposed approved drugs used for other indications.  For elimination of persistent T. 
gondii cysts, the anti-malarial endochin-like quinolones (inhibitors of the apicomplexan cytochrome 
bc1) (222), the anti-leishmanial and anti-neoplastic miltefosine (inhibitor of phosphatidylcholine 
biosynthesis and the PI3K/Akt/PKB pathway) (223, 224), and guanabenz (inhibitor of translational 
control and protein synthesis) significantly decreased the brain cyst burden in latently infected mice 
(225). Additional compounds, such as the histone deacetylase inhibitor FR235222 (226), and 
tanshinone IIA (inhibitor of inflammation and cancer cell cycle) and the antihistaminic hydroxyzine 
(227) have shown efficacy against T. gondii cysts. More validation studies are needed to select the 
compounds with the most potent cysticidal activity from these and many other approved drugs (195).  
 
Vaccines 
Vaccination may be used to prevent T. gondii infection or to clear latent infection. The long-term 
goal to control TE can be achieved by preventing its development in at-risk individuals. Therefore, 
there is a widely acknowledged need for human vaccines to reinforce the existing arsenal of anti-T. 
gondii therapeutics. Given the obvious importance of the cysts in TE, there is a need to have more in 
depth understanding of the evolutionary pressure and the molecular pathways that mediate cyst 
development and the associated immune responses. This is especially important in order to provide 
well-informed perspectives for a rational development of safe and effective vaccine capable of 
inducting potent immunity against T. gondii cysts. Given the crucial role of CD8+ CTLs in controlling 
the cysts during chronic infection, GRA6 molecules released from bradyzoites within cysts can be a 
candidate immunogen for stimulating of CD8+ CTL response (101). Hence, in designing a therapeutic 
vaccine, inclusion of full-length GRA6 protein or GRA6Nt epitope(s) to induce CD8+ T cell responses 
can be a good approach to boost immune responses against the persistent cysts. Using an adjuvant to 
induce IgG2a and switch the cytokine balance towards Th1 immune responses can potentiate the 
immunogenicity of a vaccine. An alternative preemptive vaccination strategy may involve induction of 
GRA6Nt-primed CD8+ CTLs in healthy individuals so that when immunized individuals acquire 
infection, the elicited immune response can thwart the development of new cysts, protecting the 
vaccinated individuals from developing latent infection. There is evidence that the microenvironment 
of the cystic stage is more dynamic than what was previously thought because bradyzoites’ replication 
seems to continue within the cyst, though more slowly than in tachyzoites (228).  
Several approaches to toxoplasmosis vaccine development have been explored, such as live 
attenuated strains, nanoparticle-based, exosome-based, and carbohydrate-based vaccination (229). 
Despite significant progress in vaccine discovery, including many promising proof-of-concept 
vaccination trials in mice, none of the tested vaccines has been advanced to clinical trials in humans. 
Future work toward a commercial vaccine requires detailed validation studies in order to optimize the 
potency and sustainability of the protective immunity, and practicality of administration. When 
researchers reported in the year 2014 the first application of the gene-editing tool CRISPR/CAS9 in T. 
gondii research (230), they kicked off a new era for the identification of genes with immunogenic 
potentials. Several genes have since been tested in vaccination studies in mice, which have helped to 
identify correlates of protection and candidates for generating attenuated strains of the tachyzoite stage 
(231, 232). On the downside, challenges remain as to prioritization of the most promising candidates 
from among the many fitness-conferring genes, the relevance of these candidates for the bradyzoite 
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stage and the difficulty of regulatory approval of live vaccines for human use (229, 233). Therefore, we 
must remain realistic about how soon we expect a human vaccine. T. gondii is an eukaryotic protozoan 
with a large ~69.35Mb genome and has >8,300 protein-coding genes (234). Also, this parasite has a 
complex lifecycle, with different antigenically distinct developmental stages that elicit different 
immune responses. Thus, developing a vaccine targeting several developmental stages will not be 
straightforward. Although the path to effective vaccine is full of hurdles, we should remain hopeful that 
vaccines for toxoplasmosis may, in the near future, become available for the control of toxoplasmosis. 
Finally, while a series of landmark studies have provided important contributions to current 
understanding of TE, many challenges concerning the pathogenesis and management of TE remain 
unsolved (Table 2). Overcoming these challenges is critical to successful development and realization 
of efficient therapeutic interventions. 
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FIG 1 Schematic illustration of T. gondii traversal across the BBB and the mechanisms that underlie 
the disruption of BBB permeability and brain dysfunction.  
A. The different routes of T. gondii entry into the brain and the associated alterations in the tight 
junction (TJ) proteins and adhesion molecules of the cerebrovascular endothelium. The 
extracellular tachyzoites can directly enter the brain by paracellular or transcellular route or via a 
‘Trojan horse’ mechanism where tachyzoites cross the BBB within infected leukocytes.  
B. Due to their unique metabolic and immunological attributes, neurons are often vulnerable to the 
parasite’s attack, which replicates within neurons, causing neuronal injury with production of 
cytokines and chemokines, resulting in more impairment of the neurological function and 
disturbance of brain metabolism. Neurons also provide a permissive niche to the development of 
cysts, which persist in dormancy for a long time within the brain.  
C. Following entry to the brain, the tachyzoites activate resident microglia and astrocytes and elicit 
immune responses to limit the parasite proliferation. The M1 phenotype of activated microglia 
produces pro-inflammatory cytokines, which exacerbate BBB dysfunction by altering the 
architecture of TJ proteins ZO-1, claudin-5, and occludin. The effects of M1 microglia are 
counterbalanced by alternatively activated M2 microglia, which produce anti-inflammatory 
cytokines. Maintaining this immune-inflammatory equilibrium is key to the establishment of latent 
infection. Infection of astrocytes and microglia also leads to the disruption of neuroreceptors, such 
as the α7 nAChR and N-methyl-D-aspartate receptor (NMDAR), which may lead to cognitive 
dysfunction and neurodegeneration. Activated microglia and astrocytes secrete chemokines (e.g. 
CXCL9 and CXCL10) which function as ligands for CXCR3 to promote the influx of T cells and 
myeloid cells (granulocytes and monocytes) into the brain. 
D. The matrix metalloproteinases (e.g. MMP-8 and MMP-10) and TIMP-1 also contribute to the 
regulation of the perivascular accumulation and influx of lymphocytes into the brain to prevent the 
reactivation of dormant cysts. 
E. Reactivation from latency can occur due to various mechanisms, such as reduced expression of 
VCAM-1/α4β1 integrin, CD3δ, CD4, CD8β, IFN-γ, and iNOS. Reduced levels of CXCL9, 
CXCL10, MyD88, IL-12, MMP-8 or MMP-10 during reactivated toxoplasmosis decrease the influx 
of T cells into the brain. 
 
 
FIG 2 Representative magnetic resonance images from a 68-year-old man living with HIV with 
Toxoplasma encephalitis. Images A and C are T1 FLAIR post contrast, and images B and D are the 
corresponding FLAIR. Note contrast enhancement of both lesions (A, C; bright white rim around the 
lesion), the “target sign” of the left temporal lobe lesion (white arrow), and significant mass effect (dark 






















Summary of recommendations regarding testing for toxoplasmic encephalitis (TE) 
• A positive serum anti-T. gondii IgG suggests that a patient is at risk for TE. Therefore, patients at 
risk for TE, including PLWH, individuals who will receive organ transplantation, including solid 
organ or hematopoietic stem cells, or those who will begin immunomodulatory therapies should 
be screened for serological evidence of  latent (IgG antibody) T. gondii infection in order to 
determine whether a patient is at risk of TE. 
• Lack of seropositivity for T. gondii IgG antibody indicates that TE is unlikely. 
• Seropositivity for T. gondii IgM antibody has limited utility in establishing a diagnosis of TE. 
• Diagnosis of TE is made by demonstrating clinical and radiological improvement to empiric anti-
TE therapy. Empiric therapy is most appropriate in PLWH who have CD4+ T cells <200/µl, 
reactive serum anti-T. gondii IgG, and are not receiving prophylaxis for TE. 
• CSF PCR may support the diagnosis of TE, but lumbar puncture may not be safe in individuals 
with TE because of the mass effect.  
• Lesions of TE must be differentiated from those of primary CNS lymphoma and tuberculoma or 
tuberculous abscess in PLWH.  
• In individuals receiving solid organ or hematopoietic transplants, or patients receiving 
immunomodulating therapies, TE is among a variety of potential diagnoses, including bacterial 
and fungal infections and tumefactive multiple sclerosis. 
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TABLE 2 Key questions to consider for future research 














• What drives the remarkable diversity of T. gondii in regard to its 
intermediate host range and clinical pathogenicity? 
• How does the mechanism of crossing the BBB differ among T. gondii 
strains? 
• To what extent do alterations in the actin cytoskeleton of cerebrovascular 
endothelial cells contribute to BBB disruption during T. gondii infection?  
• What parasite gene products or effectors (e.g. soluble factors, extracellular 
exosomes and their contents) induce changes in the organization or 
expression TJ proteins in endothelial cells?  
• To what extent does T. gondii interaction with non-endothelial cellular 
components of the BBB (e.g. astrocytes, microglia, pericytes) contribute to 
the pathogenesis of cerebral toxoplasmosis? 
Immunity • In which ways can trafficking and influx of CD4+ and CD8+ T cells into 
brain be modulated by MMP agonists or TIMP antagonists? 
• How do cytokines, MMPs and chemokines orchestrate T cell migration to 
and recruitment into the brain to combat toxoplasmosis? 
• How much overlap exists in the role of IL-10 originated from different 
sources in maintaining brain immune homeostasis during T. gondii 
infection?  
• How does IL-10 limit T. gondii growth while at the same time attenuate 
excessive immune responses?  







• What is the evolutionary advantage to T. gondii parasite of infecting the 
CNS?  
• Which molecular mechanisms regulate T. gondii transition from dormant 
bradyzoites to actively proliferating tachyzoites, and vice versa? 
• What are the factors that make neurons the most preferable host cell type 
and what effects the neural cell microenvironment may have on the latency 







• What can be done to improve the efficacy, safety and tolerability profiles of 
existing anti-T. gondii therapeutics? 
• Comparative studies evaluating effectiveness of different treatment 
strategies for toxoplasmosis are needed, especially for those populations of 




• Can host-targeted therapy provide new adjunctive treatments for 








• Can vaccine cocktails incorporating multiple antigens induce more effective 
anti-T. gondii immune responses than a single-antigen vaccine? What 
mechanisms might be involved? 
• What are other potent immunogenic antigens are involved in T. gondii 
immunopathogenesis and can be targeted for vaccine development? 
• Would genetically manipulated parasites be accepted by regulatory 
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